Lambutrix

Lorazepam, the active ingredient in Lambutrix, is a benzodiazepine presented as an injectable solution for intramuscular and intravenous use. It is employed to manage anxiety disorders, provide pre‑operative sedation, control acute seizures, and treat short‑term insomnia in appropriate patients. GNH USA supplies Lambutrix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lorazepam, a benzodiazepine that enhances GABA‑mediated inhibition, is indicated for several clinical situations. - Anxiety disorders: reduces excessive anxiety and tension. - Pre‑operative sedation: provides calming effect before surgical procedures. - Acute seizure control: terminates ongoing seizure activity. - Short‑term insomnia: facilitates sleep for a limited period.

Common Side Effects: - Drowsiness: feeling unusually sleepy. - Dizziness: light‑headed sensation. - Fatigue: reduced energy levels. - Impaired coordination: difficulty with fine motor tasks.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Severe hypotension: marked drop in blood pressure. - Paradoxical agitation: unexpected increase in anxiety or aggression. - Dependence and withdrawal: risk of physical dependence with abrupt discontinuation.

Lorazepam requires careful consideration of patient‑specific factors and potential risks. - Pregnancy: use only if the potential benefit justifies the potential fetal risk. - Breastfeeding: caution advised as the drug may be excreted in breast milk. - Elderly patients: start with the lowest effective dose and monitor for excessive sedation. - Concomitant CNS depressants: avoid additive sedation and respiratory depression. - Renal or hepatic impairment: dose adjustment may be necessary. - Store at controlled room temperature: keep in the original container, protect from light and moisture.

Lorazepam can interact with several drug classes, influencing its safety and efficacy. Major Interactions (Avoid): - Opioids, barbiturates, alcohol: additive CNS depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increased lorazepam levels. - Monoamine oxidase inhibitors (MAOIs): risk of severe hypotension. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced lorazepam effectiveness. - Antihistamines and certain antidepressants: may enhance sedative effects.